In a phase 2 trial of Nivolumab in patients with advanced BTC already treated with first line chemotherapy conducted by Kim and colleagues, patients with ≥1% of tumor cells expressing PD-L1 had a statistically significant higher median PFS compared with patients with PD-L1-negative tumor tissue 37. The gene discussed is CD274; the disease is neoplasm.